BASE extracts a variety of biomarker classes from proprietary database.
The database includes multiple types of molecular biomarkers (e.g., mutational patterns, CNVs beyond coding regions, somatic structural variations, gene expression).
MNM’s extensive tumor database allows for selection of a cohort of responders to a given therapy. Then, ”Biomarker Signature” is defined as a consensus biomarker set allowing to predict the response for new patients. Proprietary AI is used to optimize the biomarker signature.
Biomarker signature is a tool ready for patient stratification and can be developed into a diagnostic test.
Comprehensive infrastructure for whole genome sequencing data
Cloud-based bioinformatic solutions
Proprietary data infrastructure
Custom AI-driven platform for genomic data mining
Search for multilevel biomarker interdependencies for predictive and prognostic models